Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay
Bioorganic & Medicinal Chemistry · 2023
DOI: 10.1016/j.bmc.2023.117477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2023. Verfasst von Meiling Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, C…. Hauptthemen laut MEDLINE: TRPC Cation Channels, Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
The transient receptor potential canonical channel 5 (TRPC5), a member of the TRPC family, plays a crucial role in the regulation of various physiological activities and diseases, including those related to the central nervous system, cardiovascular system, kidney, and cancer. As a nonselective cation channel, TRPC5 mainly controls the influx of extracellular Ca2+ into cells, thereby modulating cellular depolarization and intracellular ion concentration. Inhibition of TRPC5 by small molecules presents a promising approach for the treatment of TRPC5-associated diseases. In this study, we conducted a comprehensive virtual screening of more than 1.5 million molecules from the Chemdiv database (https://www.chemdiv.com) to identify potential inhibitors of hTRPC5, utilizing the published structures and binding sites of hTRPC5 as a basis. Lipinski's rule, Veber's rule, PAINS filters, pharmacophore analysis, molecular docking, ADMET evaluation and cluster analysis methods were applied for the screening. From this rigorous screening process, 18 candidates exhibiting higher affinities to hTRPC5 were subsequently evaluated for their inhibitory effects on Ca2+ influx using a fluorescence-based assay. Notably, two molecules, namely SML-1 and SML-13, demonstrated significant inhibition of intracellular Ca2+ levels in hTRPC5-overexpressing HEK 293T cells, with IC50 values of 10.2 μM and 10.3 μM, respectively. These findings highlight SML-1 and SML-13 as potential lead molecules for the development of therapeutics targeting hTRPC5 and its associated physiological activities and diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China; University of the Chinese Academy of Sciences, Beijing 100049, C…
- Key Laboratory of Medicinal Chemistry for Natural Resource (Ministry of Education), School of Pharmacy, Yunnan University, Kunming 650091, China.
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China.
- Key Laboratory of Medicinal Chemistry for Natural Resource (Ministry of Education), School of Pharmacy, Yunnan University, Kunming 650091, China. Electronic address: xwy@ynu.edu.cn.
Zitieren
APA
Shen, M., Li, L., Li, Y., Gu, X., Bai, L., Xia, C., Xiong, W., & Zuo, Z. (2023). Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2023.117477
Vancouver
Shen M, Li L, Li Y, Gu X, Bai L, Xia C, et al. Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay. Bioorganic & Medicinal Chemistry. 2023. doi:10.1016/j.bmc.2023.117477
BibTeX
@article{Shen2023,
author = {Shen, Meiling and Li, Lingfeng and Li, Yue and Gu, Xi and Bai, Longhui and Xia, Chengfeng and Xiong, Wenyong and Zuo, Zhili},
title = {Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay},
journal = {Bioorganic & Medicinal Chemistry},
year = {2023},
doi = {10.1016/j.bmc.2023.117477}
}
EUVIMED